Across nearly every therapeutic area, investigators face the same constraints: genomics explains risk but not necessarily actual state, clinical lab values collapse human biology into blunt averages, and human heterogeneity complicates translation. There is a layer of molecular insight still missing.
Sapient’s metabolomics services, through rapid profiling of dynamic metabolites and lipids, provide rich data to explain phenotypic variability among individuals who share similar genetic backgrounds, clinical diagnoses, or lab values.
Our proprietary rapid liquid chromatography-mass spectrometry (rLC-MS) systems enable simultaneous capture of more than 15,000 metabolites and lipids per sample, in a single run – with high throughput to process thousands of samples per day.
Mass spectrometry is a key technology used to interrogate exogenous and endogenous small molecule mediators of human health and disease. However, these systems have historically been throughput-constrained, largely precluding large-scale, nontargeted metabolomics studies – until now.
Sapient has developed our proprietary rapid liquid chromatography-mass spectrometry (rLC-MS) system to overcome the bottlenecks of traditional LC-MS approaches, unlocking significant new discovery power by enabling robust, reproducible measurement of thousands of metabolites and lipids per sample, across thousands of samples at a time.
This high throughput is needed to efficiently profile the dynamic, complex landscape of human chemistry and to identify novel biomarkers and disease mechanisms not predicted by genomics or protein measures.
In fact, we have already applied rLC-MS to >67,000 human plasma samples to build our DynamiQ™ molecular-clinical database, enabling deep phenotyping to elucidate and contextualize how human biology is shaped by both endogenous physiology and environment influences over time.
Simultaneous capture of polar metabolites, polar and nonpolar lipids & bioactive lipids (15K+ per sample)
High throughput to analyze >2,000 samples per day
Up to 1,400 metabolites identified using our in-house library of >13,000 reference standards
Continuous monitoring of >500 quality metrics
Contextualization of findings in DynamiQ™
Multi-omics integration to strengthen evidence
The result? A robust, scalable solution to measure and map functional metabolic states in complex matrices.
See the power of the rLC-MS platform exemplified in this study, in which the technology was applied to analyze >26,000 plasma samples to generate novel findings, including distinct metabolic phenotypes (“metabotypes”) that may predict altered disease risk and a dynamic metabolic aging clock.
As the only metabolomics partner with a population-scale molecular-clinical database, Sapient offers the unique ability to both analyze your samples and validate the findings in independent real-world cohorts – as well as to uncover novel biology that can differentiate your programs.
Providing a robust discovery framework to map, at population-scale, the broad and dynamic landscape of human chemistry.
We have developed extensive capabilities to maximize definitive identifications of metabolite and lipid biomarkers found through our nontargeted analyses.
Our target panels enable rapid, focused analysis of specific classes of chemistries and key small molecules of interest.
Our metabolomics studies benefit from biological contextualization in Sapient’s large-scale, longitudinal reference dataset comprised of:
Build confidence in observed
biomarkers by contextualizing their disease & clinical links in independent cohorts.
Elucidate associations of observed biomarkers with dynamic health and disease trajectories.
Reveal correlated biomarker patterns within and across diseases to unlock disease subtypes and/or indication expansion opportunities.
See what makes Sapient the leader in metabolomics studies that yield actionable, decision-ready insights.
Sapient’s metabolomics workflows are built upon our proprietary rLC‑MS systems that simultaneously capture more than 15,000 metabolites and lipids per sample in a single run. This enables metabolome profiling at unprecedented depth and speed, enabling a scale of biomarker discovery previously impractical with conventional metabolomics workflows.
We also enhance the translatability of biomarkers we discover with comprehensive metabolite identification leveraging our in-house library of >13,000 chemical reference standards – enriched for key human metabolic pathways, biochemical processes, and disease drivers.
And, as the only multi-omics partner with our own molecular-clinical database comprising nontargeted metabolomics data from >67,000 human samples, we are truly unique in our ability to both analyze your samples and cross-validate key biomarker findings in real-world human cohorts.
Circulating chemistry is key to understanding the non-genetic factors that influence disease. Dynamic organ physiology, inter-organ communication, host-disease interactions, and host-environment exposures are encoded in metabolite and lipid biomarkers, providing a dynamic view into host and disease factors that modulate health status, disease pathobiology, and drug response across individuals.
Metabolomics helps to decipher heterogeneity in disease and drug response across individuals, enabling alignment of the right patient, with the right disease, with the right therapy.
For example, nontargeted metabolomics data can be used to define biologically distinct subpopulations of individuals who share similar demographics, genomics, and laboratory values but have varied molecular states correlating to very different disease risk. It can also be used to differentiate disease presence from disease mechanism, identifying subpopulations of disease with distinct, differing pathobiology.
Key use cases include:
You can also explore our metabolomics case studies and data published in collaboration with our clients.
Our metabolomics & lipidomics workflows can be applied across a wide range of matrices including plasma/serum, dried blood spots, tissues, CSF, saliva, urine, stool, and cells/media. This flexibility enables broad discovery and targeted measurement across preclinical, translational, and clinical studies.
DynamiQ provides a population-scale molecular‑clinical database in which to confirm and biologically contextualize findings uncovered in your study. It enables cross-validation in independent human samples, disease‑trajectory mapping, biomarker‑disease association analyses, and identification of biologically distinct subgroups.
DynamiQ can also be used before any sample analysis begins, using our pre-characterized samples to scout for potential biomarkers or test early hypotheses in our virtual cohorts.
Absolutely. As a multi‑omics partner, Sapient provides not only metabolomics services but also workflows to analyze proteins, cytokines, and DNA/RNA in your same samples, integrating omics layers for comprehensive mechanistic insight from regulation through downstream functional outcomes.
Connect with our scientists to discuss your project or the biological questions you want to answer. We’re here to help you design and execute a high-impact study.
"*" indicates required fields
